Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

  title={Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.},
  author={Juan W. Valle and Harpreet S Wasan and Daniel Palmer and David Cunningham and Alan Anthoney and Anthony Maraveyas and Srinivasan Madhusudan and Timothy Iveson and Sharon Hughes and Stephen P. Pereira and Michael Roughton and John A Bridgewater},
  journal={The New England journal of medicine},
  volume={362 14},
BACKGROUND There is no established standard chemotherapy for patients with locally advanced or metastatic biliary tract cancer. [] Key MethodMETHODS We randomly assigned 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin (25 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter on days 1 and 8, every 3 weeks for eight cycles) or gemcitabine alone (1000 mg per square meter on days 1, 8…

Figures and Tables from this paper

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

Cisplatin plus gemcitabine, compared with gem citabine alone, was associated with a significant survival advantage without an increase in substantial toxicity.

Long term responders to palliative chemotherapy for advanced biliary tract cancer.

From this institutional dataset, a significant proportion of patients continued chemotherapy past 8 cycles, and appeared to derive benefit from longer duration of treatment, and multivariable analysis of OS, LTR, good performance status and intrahepatic site of cancer were associated with better survival.

Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.

Gemcitabine combined with carboplatin has activity against advanced biliary tract cancers and results are comparable to other gem citabine-platinum or gemcitABine-fluoropyrimidine combinations in advanced BTCs.

Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.

This study showed that FP+cisplatin as first line and Gem based second line therapy gave a better OS rate than the reverse sequence, and showed no statistical differences in terms of response, PFS and OS.

Adjuvant Chemotherapy with Gemcitabine for Resected Biliary Tract Cancer : A Single-Arm Phase 2 Study

The present study failed to show significant benefits of gemcitabine in the adjuvant setting for patients with resected BTC, although the regimen was well tolerated.

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial

This trial confirms a mOS of 12 months with cisplatin and gemcitabine, as found in earlier trials, and should still be considered the standard first-line treatment for advanced biliary tract cancer.

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

Gemcitabine plus cisplatin combination therapy was found to be effective and well tolerated, suggesting that it could also be a standard regimen for Japanese patients.

Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer

A modified biweekly regimen of GC in ABTC is implemented in an attempt to optimize the prescribed regimen with an improved toxicity profile, added convenience to patients while maintaining efficacy, and was associated with a more favorable toxicity profile similar to that observed in prior clinical trials.

Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study

The combination of IGF shows a promising survival benefit with manageable toxicity in patients with advanced BTC and seems to be a feasible second-line treatment option for patients with rapid progression under first-line therapy with gemcitabine and cisplatin and with a good performance status.

Gemcitabine plus Cisplatin versus Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Cohort Study

GP was superior to XP in prolonging OS, despite increasing the rate of grade 3/4 adverse events, which was significantly more frequent in the GP group than in the XP group.



A randomized study of gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary tract cancer.

The combination therapy of GC would be an effective and well-tolerated chemotherapy regimen for Japanese pts with advanced BTC and the primary end-point of the study was 1- year survival rate.

Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.

This cisplatin plus gemcitabine combination schedule has a favourable toxicity profile with a discrete activity in patients with locally recurrent or metastatic squamous-cell carcinoma of the head and neck.

Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

Compared with a large randomized phase III study of GC versus MVAC, long-term survival in patients with locally advanced or metastatic transitional cell carcinoma of the urothelium treated with gemcitabine/cisplatin or methotrexate/vinblastine/doxorubicin/c isplatin was similar in both arms.

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

  • L. CrinòG. Scagliotti M. Tonato
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
The combination of gemcitabine and cisplatin induced a high response rate in both stage IIIB and IV NSCLC, with modest side effects, and deserves further careful evaluation in a phase III prospective randomized trial.

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study

C/G is associated with an improved tumour control rate, TTP and 6-month progression-free survival and the quality of life in biliary cancers for whom there is no standard chemotherapy.

Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.

The MMC + CAPE arm seems to be superior in terms of response rate, PFS and OS, and should therefore be selected for further clinical investigation in advanced biliary tract cancer.

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.

The results show that chemotherapy can add to both quantity and quality of life in advanced pancreatic and biliary cancer.

The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review.

For patients not considered candidates for surgery, but willing and able to tolerate chemotherapy alone or in combination with a fluoropyrimidine, gemcitabine appears to be a reasonable alternative to best supportive care, although this conclusion has not been confirmed with a randomized controlled trial.